Diagnosis and management of common tinea infections

American Family Physician

Volumn 58, Issue 1, 1998, Pages 163-174

  Noble, Sara L ^a   Forbes, Robert C ^a   Stamm, Pamela L ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 UNDECENOIC ACID; ALLYLAMINE; ANTIFUNGAL AGENT; ASTEMIZOLE; BARBITURIC ACID DERIVATIVE; BUTENAFINE; CICLOPIROX; CICLOPIROXOLAMINE; CIMETIDINE; CISAPRIDE; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; GRISEOFULVIN; HALOPROGIN; IMIDAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MICONAZOLE NITRATE; NAFTIFINE; ORAL CONTRACEPTIVE AGENT; OXICONAZOLE; PHENYTOIN; RIFAMPICIN; RITONAVIR; SULCONAZOLE; TERBINAFINE; TERFENADINE; TOLNAFTATE; UNINDEXED DRUG; WARFARIN;

ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; IMPOTENCE; LIVER TOXICITY; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRURITUS; TINEA; TINEA CAPITIS; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; TRICHOPHYTON;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; PATIENT EDUCATION; TEACHING MATERIALS; TINEA;

EID: 0031874544     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Cohn MS. Superficial fungal infections. Topical and oral treatment of common types. Postgrad Med 1992;91:239-44,249-52.
2. Pierard GE, Arrese JE, Pierard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs 1996;52:209-24.
3. Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994;31(3 Pt 2):S21-5.
4. Habif TP. Superficial fungal infections. In: Habif P, ed. Clinical dermatology: a color guide to diagnosis and therapy. 3d ed. St. Louis: Mosby, 1996:362-408.
5. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hardinsky MK, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol 1996;34(2 Pt 1):282-6.
6. Hay R. Dermatophytosis and other superficial mycoses. In: Mandell GL, Douglas RG, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:2375-86.
7. Bergus GR, Johnson JS. Superficial tinea infections. Am Fam Physician 1993;48:259-68.
8. Lesher J, Levine N, Treadwell P. Fungal skin infections. Patient Care 1994;28:16-44.
9. Lopez-Gomez S, Del Palacio A, Van Cutsem J, Soledad Cuetara M, Iglesias L, Rodriguez-Noriega A. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. Int J Dermatol 1994;33:743-7.
10. Haroon TS, Hussain I, Aman S, Jahangir M, Kazmi AH, Sami AR, et al. A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Br J Dermatol 1996;135:86-8.
11. Elewski BE. Cutaneous mycoses in children. Br J Dermatol 1996;134(Suppl 46):7-11.
12. Farag A, Taha M, Halim S. One-week therapy with oral terbinafine in cases of tinea cruris/corporis. Br J Dermatol 1994;131:684-6.
13. Parent D, Decroix J, Heenen M. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. Dermatology 1994;189:378-81.
14. Lachapelle JM, DeDoncker P, Tennestedt D, Cauwenbergh G, Janssen PA. Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manus: an interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile. Dermatology 1992;184:45-50.
15. Voravutinon V. Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. J Med Assoc Thai 1993;76:388-93.
16. Pariser DM, Pariser RJ, Ruoff G, Ray TL. Double-blind comparison of itraconazole and placebo in the treatment of tinea corporis and tinea cruris. J Am Acad Dermatol 1994;31(2 Pt 1):232-4.
17. Suchil P, Gei FM, Robles M, Perera-Ramirez A, Welsh O, Male O. Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea corporis/cruris and cutaneous candidiasis. Clin Exp Dermatol 1992;17:397-401.
18. Montero-Gei F, Perera A. Therapy with fluconazole for tinea corporis, tinea cruris, and tinea pedis. Clin Infect Dis 1992;14(Suppl 1):S77-81.
19. Wishart JM. A double blind study of itraconazole vs. griseofulvin in patients with tinea pedis and tinea manus. N Z Med J 1994;107:126-8.
20. Elewski B, Hay RJ. International summit on cutaneous antifungal therapy. J Am Acad Dermatol 1995;33(5 Pt 1):816-22.
21. Sporanox. Package insert. Janssen Pharmaceutica Inc., 1997.
22. Lamisil. Package insert. Sandoz Pharmaceuticals Corporation, 1997.
23. Physicians' desk reference. 52nd ed. Montvale, N.J.: Medical Economics, 1998.
24. DeDoncker P, Decroix J, Pierard GE, Roelant D, Woestenborghs R, Jacqmin P, et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996;132:34-41.
25. DeDoncker P, Van Lint J, Dockx P, Roseeuw D. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995;56:180-3.
26. Tosti A, Piraccini BM, Stinchi C, Venturo N, Bardazzi F, Colombo MD. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996;34:595-600.
27. Nahass GT, Sisto M. Onychomycosis: successful treatment with once-weekly fluconazole. Dermatology 1993;186:59-61.
28. Smith SW, Sealy DP, Schneider E, Lackland D. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. South Med J 1995;88:1217-20.
29. Coldiron B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992;128:909-10.
30. Diehl KB. Topical antifungal agents: an update. Am Fam Physician 1996;54:1687-92.
31. Red book. Montvale, N.J.: Medical Economics Data, 1998.
32. Elewski B. Tinea capitis. Dermatol Clin 1996;14:23-31.
33. Korting HC, Schafer-Korting M, Zienicke H, Georgii A, Ollert MW. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with itraconazole. Antimicrob Agents Chemother 1993;37:2064-8.
34. Abdel-Rahman SM, Nahata MC. Treatment of tinea capitis. Ann Pharmacother 1997;31:338-48.
35. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994;30(6):911-33.
36. Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995;39:1671-5.
37. Allen J. Itraconazole and ketoconazole absorption in achlorhydria. Prescriber's Lett 1997;4(1):1-6.
38. Diflucan. Package insert. Pfizer Inc., 1997.
39. Nizoral. Package insert. Janssen Pharmaceutica Inc., 1997.
40. Korting HC, Schafer-Korting M. Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin. Arch Dermatol 1992;128:243-8.
41. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993;29:S50-4.
42. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994;30(5 Pt 1):677-98.